Table 2.
Characteristics of AML patient samples used in inhibitor screen
| Sample no. | Age, y/sex | Status | Cytogenetics | ITD length, bp | Mutant, % |
|---|---|---|---|---|---|
| 1 | 53/F | Diagnostic | INV16 | 78 | 5 |
| 2 | 75/M | Diagnostic | Normal | 39 | 31 |
| 3 | 58/M | Diagnostic | Normal | 96 | 35 |
| 4 | 28/M | Diagnostic | Normal | 75 | 37 |
| 5 | 58/F | Diagnostic | Normal | 33 | 42 |
| 6 | 69/F | Diagnostic | Normal | 33 | 43 |
| 7 | 54/F | Diagnostic | Normal | 51 | 70 |
| 8 | 26/M | Diagnostic | Normal | 51 | 9 |
| 9 | 64/M | Relapse | Normal | 21 | 95 |
| 10 | 53/M | Relapse | Normal | 18 | 91 |
| 11 | 53/F | Relapse | +8,13,22 | 39 | 55 |
| 12 | 34/M | Relapse | t(7;11) | 201 | 55 |
| 13 | 55/M | Relapse | Normal | 30 | 96 |
| 14 | 59/F | Diagnostic | Normal | — | — |
| 15 | 62/M | Diagnostic | t(11;19) | — | — |
| 16 | 69/F | Diagnostic | Normal | — | — |
| 17 | 23/F | Diagnostic | INV16 | — | — |
| 18 | 71/M | Diagnostic | Normal | — | — |
| 19 | 70/M | Diagnostic | Normal | — | — |
| 20 | 78/F | Diagnostic | Normal | — | — |
| 21 | 68/F | Diagnostic | Normal | — | — |
| 22 | 28/M | Diagnostic | t(11;19) | — | — |
| 23 | 40/M | Diagnostic | Normal | — | — |
| 24 | 25/F | Relapse | t(9;11) | — | — |
| 25 | 60/F | Relapse | Normal | — | — |
| 26 | 50/M | Relapse | Normal | — | — |
| 27 | 55/F | Relapse | Normal | — | — |
Peripheral blood blasts were obtained through an institutional review board–approved protocol at diagnosis or relapse. F indicates female; M, male; and —, wild-type FLT3.